---
title: "VivoSim Labs faces Nasdaq minimum bid price deficiency notice, risks delisting if noncompliance persists"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296648519.md"
description: "VivoSim Labs received a Nasdaq deficiency notice for maintaining a sub-$1 bid price for 30 consecutive days. The company has until February 16, 2027, to restore compliance by keeping shares above $1 for ten consecutive trading days. Failure to comply risks delisting, though an extension may be available. Potential remedies include a reverse stock split with ratios ranging from 1-for-5 to 1-for-20."
datetime: "2026-08-21T20:06:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296648519.md)
  - [en](https://longbridge.com/en/news/296648519.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296648519.md)
generator: "portal-rs"
---

# VivoSim Labs faces Nasdaq minimum bid price deficiency notice, risks delisting if noncompliance persists

-   Nasdaq issued a noncompliance notice on Aug. 17, 2026, citing a sub-$1 bid price for 30 consecutive business days. \* Shares keep trading on the Nasdaq Capital Market under VIVS, with no immediate impact on listing status. \* Compliance deadline set for Feb. 16, 2027; stock must close at or above $1 for 10 consecutive business days. \* Failure to cure could trigger delisting risk, though an additional 180-day extension may be available if eligibility conditions are met. \* Options include a shareholder-approved reverse stock split, with a proposed ratio range of 1-for-5 to 1-for-20. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-361085), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [VIVS.US](https://longbridge.com/en/quote/VIVS.US.md)

## Related News & Research

- [VivoSim Labs plans rat liver model expansion for NAMkind platform](https://longbridge.com/en/news/297649874.md)
- [VivoSim Labs to Add Rat Liver Model to NAMkind Platform | VIVS Stock News](https://longbridge.com/en/news/297650557.md)
- [VivoSim Labs Chief Commercial Officer Lialin Tony Serge acquires common shares valued at $2,804](https://longbridge.com/en/news/297691554.md)
- [Exascale Labs Holdings Announced Transfer or Voluntary Withdrawal of Listing](https://longbridge.com/en/news/297805044.md)
- [BioAge Labs to present at Citi Biopharma Back to School Conference fireside chat](https://longbridge.com/en/news/297782949.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**